Atossa Therapeutics Stock Forecast, Price & News

-0.17 (-7.02 %)
(As of 05/6/2021 12:04 PM ET)
Today's Range
50-Day Range
52-Week Range
Volume183,836 shs
Average Volume20.18 million shs
Market Capitalization$271.85 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive ATOS News and Ratings via Email

Sign-up to receive the latest news and ratings for Atossa Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:ATOS
Year FoundedN/A

Sales & Book Value

Annual SalesN/A
Book Value$1.37 per share


Net Income$-17,240,000.00




Market Cap$271.85 million
Next Earnings Date5/12/2021 (Estimated)
OptionableNot Optionable


See More Headlines
Atossa Therapeutics logo

About Atossa Therapeutics

Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines in the areas of oncology and infectious diseases. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It is also developing AT-301, a proprietary drug candidate for nasal administration in patients diagnosed with COVID-19; AT-H201, a drug candidate to improve lung function in COVID-19 patients; and immunotherapy/chimeric antigen receptor therapy programs for the treatment of breast cancer. Atossa Therapeutics, Inc. has a research agreement with Dana-Farber Cancer Institute, Inc. to support research of cytokine-coated nanoparticles for the potential treatment of breast cancer. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.


Overall MarketRank

1.20 out of 5 stars

Medical Sector

920th out of 2,043 stocks

Pharmaceutical Preparations Industry

431st out of 771 stocks

Analyst Opinion: 3.5Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Atossa Therapeutics (NASDAQ:ATOS) Frequently Asked Questions

Is Atossa Therapeutics a buy right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Atossa Therapeutics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Atossa Therapeutics stock.
View analyst ratings for Atossa Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Atossa Therapeutics?

Wall Street analysts have given Atossa Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Atossa Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Atossa Therapeutics?

Atossa Therapeutics saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 10,040,000 shares, an increase of 52.4% from the March 15th total of 6,590,000 shares. Based on an average daily volume of 22,790,000 shares, the days-to-cover ratio is presently 0.4 days.
View Atossa Therapeutics' Short Interest

When is Atossa Therapeutics' next earnings date?

Atossa Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, May 12th 2021.
View our earnings forecast for Atossa Therapeutics

How were Atossa Therapeutics' earnings last quarter?

Atossa Therapeutics, Inc. (NASDAQ:ATOS) issued its earnings results on Tuesday, March, 30th. The company reported ($0.88) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.27) by $0.61.
View Atossa Therapeutics' earnings history

How has Atossa Therapeutics' stock price been impacted by Coronavirus?

Atossa Therapeutics' stock was trading at $0.88 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, ATOS stock has increased by 159.1% and is now trading at $2.28.
View which stocks have been most impacted by COVID-19

When did Atossa Therapeutics' stock split? How did Atossa Therapeutics' stock split work?

Atossa Therapeutics's stock reverse split on Friday, April 20th 2018. The 1-12 reverse split was announced on Friday, April 20th 2018. The number of shares owned by shareholders was adjusted after the market closes on Thursday, April 19th 2018. An investor that had 100 shares of Atossa Therapeutics stock prior to the reverse split would have 8 shares after the split.

What price target have analysts set for ATOS?

2 brokers have issued 1-year price targets for Atossa Therapeutics' stock. Their forecasts range from $7.00 to $8.00. On average, they expect Atossa Therapeutics' stock price to reach $7.50 in the next year. This suggests a possible upside of 228.9% from the stock's current price.
View analysts' price targets for Atossa Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Atossa Therapeutics' key executives?

Atossa Therapeutics' management team includes the following people:
  • Dr. Steven C. Quay, Chairman, CEO & Pres (Age 70, Pay $919.59k)
  • Mr. Kyle Guse C.P.A., Esq., CPA, CFO, Gen. Counsel & Sec. (Age 57, Pay $629.18k)
  • Ms. Janet Rose Rea, Sr. VP of Regulatory, Quality & Clinical Affairs

What is Steven C. Quay's approval rating as Atossa Therapeutics' CEO?

8 employees have rated Atossa Therapeutics CEO Steven C. Quay on Steven C. Quay has an approval rating of 53% among Atossa Therapeutics' employees. This puts Steven C. Quay in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Atossa Therapeutics' key competitors?

What other stocks do shareholders of Atossa Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Atossa Therapeutics investors own include AVEO Pharmaceuticals (AVEO), Alibaba Group (BABA), Heat Biologics (HTBX), Vaxart (VXRT), Biocept (BIOC), MannKind (MNKD), Biopharmx (BPMX), Daré Bioscience (DARE), OPKO Health (OPK) and Nokia (NOK).

What is Atossa Therapeutics' stock symbol?

Atossa Therapeutics trades on the NASDAQ under the ticker symbol "ATOS."

Who are Atossa Therapeutics' major shareholders?

Atossa Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include Commonwealth Equity Services LLC (0.03%) and Royal Fund Management LLC (0.01%).
View institutional ownership trends for Atossa Therapeutics

Which major investors are buying Atossa Therapeutics stock?

ATOS stock was bought by a variety of institutional investors in the last quarter, including Commonwealth Equity Services LLC, and Royal Fund Management LLC.
View insider buying and selling activity for Atossa Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Atossa Therapeutics?

Shares of ATOS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Atossa Therapeutics' stock price today?

One share of ATOS stock can currently be purchased for approximately $2.28.

How much money does Atossa Therapeutics make?

Atossa Therapeutics has a market capitalization of $275.48 million.

How many employees does Atossa Therapeutics have?

Atossa Therapeutics employs 6 workers across the globe.

What is Atossa Therapeutics' official website?

The official website for Atossa Therapeutics is

Where are Atossa Therapeutics' headquarters?

Atossa Therapeutics is headquartered at 107 SPRING STREET, SEATTLE WA, 98104.

How can I contact Atossa Therapeutics?

Atossa Therapeutics' mailing address is 107 SPRING STREET, SEATTLE WA, 98104. The company can be reached via phone at 206-325-6086 or via email at [email protected]

This page was last updated on 5/6/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.